Trial Profile
An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Oral Doses of DEB025 in Subjects With Mild and Moderate Hepatic Impairment Compared to Matched Healthy Subjects With Normal Liver Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs Alisporivir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 27 Apr 2016 Primary end points has been modified
- 25 Sep 2013 New trial record